Related Experiment Videos
Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates
Insights
This study tracked cefotaxime levels in neonates, finding peak plasma concentrations and half-lives varied during treatment. Careful blood sample handling is crucial for accurate cefotaxime and desacetyl-cefotaxime measurements in infants.
Area of Science:
- Neonatal pharmacology
- Antibiotic pharmacokinetics
- Pediatric infectious diseases
Background:
- Cefotaxime is a third-generation cephalosporin antibiotic used to treat infections in neonates.
- Understanding cefotaxime pharmacokinetics in neonates is crucial for optimizing therapeutic efficacy and minimizing toxicity.
- Previous studies on neonatal cefotaxime metabolism and excretion have yielded varying results.
Purpose of the Study:
- To determine the pharmacokinetic profile of cefotaxime in neonates receiving intravenous therapy.
- To measure plasma concentrations of cefotaxime and its active metabolite, desacetyl-cefotaxime.
- To assess the impact of sample handling on assay accuracy.
Main Methods:
- Neonates received cefotaxime intravenously at 25 mg/kg every 12 hours.
- Blood samples were collected via heel-prick and specially treated to prevent hemolysis.
- Plasma concentrations of cefotaxime and desacetyl-cefotaxime were measured over the first three days of therapy.
Main Results:
- Mean peak plasma cefotaxime concentrations ranged from 40-52 mg/l during the first three days.
- Mean plasma half-lives for cefotaxime were between 2.7-4.0 hours.
- Mean peak desacetyl-cefotaxime concentrations were approximately one-quarter of cefotaxime levels, lower than previously reported in neonates.
Conclusions:
- Neonatal cefotaxime pharmacokinetics exhibit variability in peak concentrations and half-lives.
- Observed desacetyl-cefotaxime levels were lower than expected compared to adult studies and prior neonatal research.
- Meticulous sample preparation is essential for accurate quantification of cefotaxime and desacetyl-cefotaxime in neonatal biological samples.
Abstract:
Cefotaxime was given to neonates as treatment of infection in a dose of 25 mg/kg 12 hourly by intravenous injection. Blood samples taken by heel-prick were specially treated to minimize any effect of haemolysis on the hydrolysis of cefotaxime. The mean peak plasma concentrations of cefotaxime on the first, second and third days of therapy were 43, 40 and 52 mg/l, respectively, with mean plasma half lives of 4.0, 2.7 and 3.2 h. The mean peak concentrations of desacetyl-cefotaxime were about a quarter of those of cefotaxime, which is in good agreement with adult studies, but much lower than those previously published in studies with neonates. These results emphasize the care that is necessary in the assay of body fluids and tissues for cefotaxime and desacetyl-cefotaxime if accurate results are to be obtained.